The six TRAIL-R2–binding repeat units were then linked to polyethylene glycol-20 (PEG20) to improve in vivo half-life to generate MEDI3039, which has picomolar activity in a range of cancer cell line models and enhanced monotherapy activity in vivo compared with previously developed recombinant forms of TRAIL and first-generation agonists. This evidence concerns the gene TNFRSF10B and cancer.